Here are the 10-K annual reports from Fulgent Genetics, Inc. (FLGT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow FLGT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLGT filings page.
Fulgent Genetics files its annual report describing a dual business in diagnostic laboratory services and cancer therapeutics. The company combines broad pathology and genetic testing with a nanoencapsulation drug platform, including FID-007 in Phase 2 for head and neck cancer and FID-022 in an early Phase 1/1b trial.
One aggregated customer represented 22% of revenue in both 2025 and 2024, highlighting customer concentration risk. The report outlines extensive U.S. and international regulatory oversight of its labs and drug development, plus evolving rules for lab-developed tests and European IVDR compliance.
The filing notes an aggregate market value of non‑affiliate equity of about $284.3 million as of June 30, 2025, and 31,230,632 common shares outstanding as of February 23, 2026.